333,200 Shares in Omnicell, Inc. (NASDAQ:OMCL) Acquired by Oberweis Asset Management Inc.

Oberweis Asset Management Inc. purchased a new stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 333,200 shares of the company's stock, valued at approximately $14,834,000. Oberweis Asset Management Inc. owned approximately 0.72% of Omnicell as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the stock. Sumitomo Mitsui Trust Group Inc. increased its stake in Omnicell by 93.3% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock worth $64,573,000 after purchasing an additional 699,925 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Omnicell by 31.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock valued at $73,127,000 after acquiring an additional 394,820 shares during the period. Victory Capital Management Inc. boosted its stake in Omnicell by 32.9% in the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company's stock worth $67,951,000 after purchasing an additional 377,883 shares during the period. Renaissance Technologies LLC grew its position in Omnicell by 79.3% during the 4th quarter. Renaissance Technologies LLC now owns 456,343 shares of the company's stock worth $20,316,000 after purchasing an additional 201,831 shares in the last quarter. Finally, Cramer Rosenthal Mcglynn LLC purchased a new stake in shares of Omnicell in the fourth quarter valued at $7,703,000. 97.70% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on OMCL. Wells Fargo & Company reduced their price objective on Omnicell from $40.00 to $38.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Benchmark reissued a "buy" rating and issued a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. StockNews.com upgraded Omnicell from a "hold" rating to a "buy" rating in a report on Tuesday, April 15th. Bank of America reduced their target price on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a report on Monday, January 6th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday, March 20th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Omnicell has a consensus rating of "Hold" and a consensus price target of $50.67.

Omnicell Stock Up 2.6 %

Shares of OMCL opened at $30.69 on Thursday. The company has a 50-day simple moving average of $34.67 and a 200-day simple moving average of $41.03. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The firm has a market capitalization of $1.44 billion, a P/E ratio of 113.67, a P/E/G ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, equities research analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.